Literature DB >> 9252383

Presenilins are processed by caspase-type proteases.

H Loetscher1, U Deuschle, M Brockhaus, D Reinhardt, P Nelboeck, J Mous, J Grünberg, C Haass, H Jacobsen.   

Abstract

Presenilin 1 (PS1) and presenilin 2 (PS2) are endoproteolytically processed in vivo and in cell transfectants to yield 27-35-kDa N-terminal and 15-24-kDa C-terminal fragments. We have studied the cleavage of PS1 and PS2 in transiently and stably transfected hamster kidney and mouse and human neuroblastoma cells by immunoblot and pulse-chase experiments. C-terminal fragments were isolated by affinity chromatography and SDS-polyacrylamide gel electrophoresis and sequenced. The processing sites identified in PS1 and PS2 (Asp345/Ser346 and Asp329/Ser330, respectively) are typical for caspase-type proteases. Specific caspase inhibitors and cleavage site mutations confirmed the involvement of caspase(s) in PS1 and PS2 processing in cell transfectants. Fluorescent peptide substrates carrying the PS-identified cleavage sites were hydrolyzed by proteolytic activity from mouse brain. The PS2-derived peptide substrate was also cleaved by recombinant human caspase-3. Additional processing of PS2 by non-caspase-type proteases was also observed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252383     DOI: 10.1074/jbc.272.33.20655

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  Presenilins: structural aspects and posttranslational events.

Authors:  F Checler
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

2.  C-terminal maturation fragments of presenilin 1 and 2 control secretion of APP alpha and A beta by human cells and are degraded by proteasome.

Authors:  C A da Costa; K Ancolio; F Checler
Journal:  Mol Med       Date:  1999-03       Impact factor: 6.354

Review 3.  Metabolism of presenilins.

Authors:  G Thinakaran
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

4.  Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death.

Authors:  C Stadelmann; T L Deckwerth; A Srinivasan; C Bancher; W Brück; K Jellinger; H Lassmann
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 5.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

6.  Increased production of amyloid precursor protein provides a substrate for caspase-3 in dying motoneurons.

Authors:  N Y Barnes; L Li; K Yoshikawa; L M Schwartz; R W Oppenheim; C E Milligan
Journal:  J Neurosci       Date:  1998-08-01       Impact factor: 6.167

7.  Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production.

Authors:  J N Keller; Q Guo; F W Holtsberg; A J Bruce-Keller; M P Mattson
Journal:  J Neurosci       Date:  1998-06-15       Impact factor: 6.167

8.  Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease.

Authors:  F Yang; X Sun; W Beech; B Teter; S Wu; J Sigel; H V Vinters; S A Frautschy; G M Cole
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

9.  Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons.

Authors:  Cristine Alves da Costa; Erwan Paitel; Mark P Mattson; Robert Amson; Adam Telerman; Karine Ancolio; Frédéric Checler; Marc P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

10.  Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis.

Authors:  J Walter; A Schindzielorz; J Grünberg; C Haass
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.